FDA approves Regeneron’s Dupixent for bullous pemphigoid?

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Regeneron Pharmaceuticals’ biologics license application (BLA) or supplemental BLA (sBLA) for Dupixent® (dupilumab) as a treatment for bullous pemphigoid by June 20, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.